-transparent.png){kind=logo}
Cyclosporin A (CsA) is now widely used in the prevention/treatment of graft rejection and in the treatment of some human inflammatory diseases. We studied the effect of CsA on the release of chemical mediators from human lung mast cells in vitro. CsA (0.03-3 micrograms/ml) inhibited the release of histamine and prostaglandin D2 induced by anti-IgE from lung mast cells. CsA-induced inhibition of mediator release was not abolished by washing the cells before stimulation and it was not affected by the degree of purity of mast cell preparations. Our results indicate that CsA, in pharmacological concentrations, is a rapid and irreversible inhibitor of the release of preformed and de novo synthesized mediators from human lung mast cells. These findings might explain, at least in part, some of the therapeutic actions of CsA in vivo.
M Triggiani, and
R Cirillo, and
L M Lichtenstein, and
G Marone
May 2005,
Journal of pharmacological sciences,
M Triggiani, and
R Cirillo, and
L M Lichtenstein, and
G Marone
April 1990,
Agents and actions,
M Triggiani, and
R Cirillo, and
L M Lichtenstein, and
G Marone
May 1985,
British journal of clinical pharmacology,
M Triggiani, and
R Cirillo, and
L M Lichtenstein, and
G Marone
March 1993,
Annals of allergy,
M Triggiani, and
R Cirillo, and
L M Lichtenstein, and
G Marone
January 1963,
Surgical forum,
M Triggiani, and
R Cirillo, and
L M Lichtenstein, and
G Marone
June 2004,
Acta pharmacologica Sinica,
M Triggiani, and
R Cirillo, and
L M Lichtenstein, and
G Marone
March 1986,
Arzneimittel-Forschung,
M Triggiani, and
R Cirillo, and
L M Lichtenstein, and
G Marone
August 1996,
Biochemical and biophysical research communications,
M Triggiani, and
R Cirillo, and
L M Lichtenstein, and
G Marone
March 1987,
Biochemical and biophysical research communications,
M Triggiani, and
R Cirillo, and
L M Lichtenstein, and
G Marone
January 2018,
European journal of pharmacology,
